RECEF (Recce Pharmaceuticals) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 26, 2026)


RECEF Recce Pharmaceuticals Ltd RECEF
31 GF Score
Price $0.22
! 4 Warning Signs
View Full Analysis

What is Recce Pharmaceuticals Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Recce Pharmaceuticals's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

RECEF vs VRTX, REGN, ALNY: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Recce Pharmaceuticals's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Recce Pharmaceuticals Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Recce Pharmaceuticals's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Recce Pharmaceuticals's Margin of Safety % (DCF Earnings Based) falls into.


RECEF
31GF Score
Recce Pharmaceuticals Ltd RECEF
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Recce Pharmaceuticals Business Description

Other Exchanges R9Q:GermanyRCE:Australia
Address 3 Brodie Hall Drive, Suite 10, Technology Park, Bentley, WA, AUS, 6102
Recce Pharmaceuticals Ltd is an Australia-based, globally-focused biotechnology company that is pioneering the development and commercialisation of a drug discovery and development business commercialising new Classes of synthetic anti-infectives with broad-spectrum activity designed to address the urgent health threat of antibiotic-resistant superbugs and emerging viral pathogens. Its patented candidate, RECCE 327, has been developed for the treatment of life-threatening bacterial infections. It has one segment, which is the research and development of pharmaceutical drugs. Geographic segments are Australia, the UK, and the USA, of which the majority of the revenue comes from Australia. It offers antibiotic drugs to treat bacterial infections for Sepsis, Escherichia coli, and Others.
31GF Score

Get the complete analysis for RECEF

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.22
Price